How to capture real-world data to prove efficacy of repurposed drugs?
As drug repurposing, or using existing drugs for news indications, is an important pillar of the Anticancer Fund’s strategy to treat cancer, we participate to the annual event of C-Path’s CURE Drug Repurposing Collaboratory, on the 16th and 17th of November.
The CURE Drug Repurposing Collaboratory (CDRC) is a public-private partnership initiated in June 2020 by C-Path and the U.S. Food and Drug Administration (FDA) in partnership with the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH).
The main goal of the organisation is to capture clinical data to advance drug repurposing and inform future trials. Many approved drugs have therapeutic uses that are never fully identified or developed, because there is no business case behind it.
We participate to the three-day event, a public webinar with key opinion leaders and experts, to discuss how data should be captured to generate hypothesis regarding treatment efficacy.
On the first day our Program Director Drug Repurposing, Pan Pantziarka, will explain how he gains data about repurposed drugs to treat sarcoma. Sarcoma is a rare kind of cancer that occurs in the bones and in the soft tissues.
Day two will focus on the legislatives challenges drug repurposing is encountering, especially to move some drugs from “off-label” to “on-label”. Lydie Meheus, Managing Director of the Anticancer Fund, will underline the role of non-profits in advancing drug repurposing.
“Happy to participate in this collaborative effort. It’s an unique international forum to think out-of-the-box and to come up with solutions for all stakeholders dealing with the drug repurposing challenges. Bridging between regulators/payers, industry, clinicians and patients is an important role for learned non-profits", says Lydie Meheus.
After both speakers presentations, a debate will be organised to elaborate on the topic. The audience will get the opportunity to ask questions to the panelists, so please join.
To register for the event, please click here.